Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Acumen Pharmaceuticals is a clinical-stage biotechnology company developing ACU193, a monoclonal antibody targeting soluble amyloid-beta oligomers (AβOs) for Alzheimer's disease treatment. The company is currently conducting Phase 1 clinical trials with no approved products or revenue, relying entirely on cash reserves and equity financing. The stock trades on clinical trial milestones, regulatory updates, and Alzheimer's therapeutic landscape developments.
Acumen operates as a pure R&D entity burning cash to advance ACU193 through clinical trials. The business model depends on successfully demonstrating safety and efficacy in Alzheimer's patients, obtaining FDA approval, and commercializing the therapy. Competitive differentiation lies in targeting soluble AβOs rather than amyloid plaques, potentially offering earlier intervention with fewer side effects than competitors like Leqembi or Kisunla. Monetization requires either independent commercialization (requiring significant capital raise) or partnership/acquisition by larger pharmaceutical companies. The company has no pricing power until regulatory approval and market entry.
Phase 1 clinical trial data readouts - safety, tolerability, and pharmacokinetic/pharmacodynamic results for ACU193
Regulatory milestones - IND submissions for Phase 2, FDA feedback on trial design, breakthrough therapy designation potential
Competitive landscape shifts - approval/failure of competing anti-amyloid therapies (Eli Lilly, Eisai, Roche programs)
Partnership announcements or acquisition speculation from large-cap pharma seeking Alzheimer's pipeline assets
Cash runway updates - quarterly burn rate, financing announcements, dilution concerns driving 50%+ volatility
Clinical trial failure risk - Phase 1 safety issues or lack of efficacy signal could terminate ACU193 program entirely, rendering equity worthless
Regulatory pathway uncertainty - FDA may require larger, longer trials than anticipated given mixed results from other anti-amyloid therapies and safety concerns (ARIA-E edema)
Alzheimer's therapeutic paradigm shift - emerging evidence questioning amyloid hypothesis could devalue entire anti-amyloid pipeline class
Reimbursement environment - CMS coverage restrictions on Alzheimer's therapies (as seen with Aduhelm) could limit commercial viability even if approved
Established competitors with approved therapies - Eli Lilly's Kisunla and Eisai/Biogen's Leqembi have first-mover advantage and clinical validation
Well-funded pipeline competition - Roche, AbbVie, and others developing alternative Alzheimer's mechanisms (tau, inflammation) with potentially superior profiles
Acquisition target risk - larger competitors could acquire Acumen at unfavorable valuations if clinical data is promising but company lacks financing
Cash runway depletion - current burn rate of ~$25-30M quarterly suggests 12-18 month runway, requiring dilutive financing in 2026-2027
Equity dilution risk - future capital raises at depressed valuations could significantly dilute existing shareholders given $200M market cap
Negative equity trajectory - ROE of -97.4% reflects accumulated losses exceeding equity base, typical for clinical-stage but signals no near-term profitability
low - Clinical-stage biotechs are largely insulated from GDP fluctuations as they have no commercial operations. However, economic downturns can tighten venture capital and public equity markets, making financing more difficult and expensive. Severe recessions may delay trial timelines if contract research organizations face capacity constraints or if patient recruitment slows due to healthcare access issues.
Rising interest rates negatively impact Acumen through two channels: (1) Higher discount rates compress the present value of distant future cash flows (post-2028 potential revenues), making speculative biotech valuations less attractive relative to bonds; (2) Tighter financial conditions reduce risk appetite for pre-revenue equities, increasing cost of capital for future financing rounds. The company's $120M+ cash position earns modestly higher yields in rising rate environments, but this is immaterial versus valuation compression. Rate cuts would be positive for speculative growth equity valuations.
minimal - Acumen has low debt levels (Debt/Equity 0.33) and operates primarily on equity financing. Credit market conditions matter only for future convertible debt issuance possibilities or acquisition financing by potential acquirers. The company is not dependent on credit availability for operations.
growth/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from clinical-stage biotech binary outcomes. Typical holders include specialized healthcare hedge funds, biotech-focused venture investors, and retail speculators betting on acquisition or clinical success. The 74.5% one-year return reflects momentum trading around clinical milestones. Not suitable for value or income investors given no earnings, dividends, or tangible asset base. Requires 3-5 year investment horizon minimum to see Phase 2/3 data.
high - Clinical-stage biotechs exhibit extreme volatility with 50-100% single-day moves common on trial data releases. The stock's 52.4% three-month return demonstrates momentum sensitivity. Beta likely exceeds 2.0 versus broader market. Illiquidity (small market cap, limited institutional ownership) amplifies price swings. Options market typically prices implied volatility above 80-100% around data catalysts.